Last updated: 2026-10-19 17:34:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Arvinas, Inc. (ARVN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $7.20, with a market capitalization of $455.74M and a P/E ratio of 49.00. Over the past 52 weeks, its price has ranged from $6.74 to $14.51. This page covers its latest market performance, valuation, price trends and company information.
$455.74M | |
$7.06 | |
$108.47 | |
$5.90 | |
$6.97 | |
338.25K | |
804.36K | |
49.00 | |
$14.51 | |
$6.74 | |
-- | |
-- |
Arvinas, Inc. (ARVN) is currently trading at $7.20 as of 2026-10-19 17:18:10, up 3.23% ($0.23) from the previous close of $6.97
During today's regular trading session, ARVN has traded between $5.90 and $108.47, with a trading volume of 338.25K shares. The current price is near the lower end of today's range.
Over the past seven days, Arvinas, Inc. (ARVN) moved from $7.51 to $7.20, representing a decline of 4.19% ($0.31).
The stock traded between $6.74 and $7.74 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 736.65 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 5.9%
ARVN is currently trading at $7.20, placing it 5.9% of the way from its 52-week low of $6.74 to its 52-week high of $14.51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 246 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Arvinas, Inc. (ARVN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.